Novo Nordisk sets up stem cell manufacturing in California, US

By Flora Southey contact

- Last updated on GMT

(Image: Getty/CIPhotos)
(Image: Getty/CIPhotos)

Related tags: Novo nordisk, Stem cell

Novo Nordisk will take over the lease of a manufacturing facility in Fremont, California, where the company will make stem cell-based therapies with optionally licensed technology.

According to the agreement, Novo Nordisk will pay US biotech Asterias Biotherapeutics $1bn (€868m) to sublease the 44,000 square-foot facility through to December 31, 2021.

The site, located in Fremont, California, can be used to manufacture pluripotent stem cells, including human embryonic stem (hES) cells, under current good manufacturing practices (cGMP).

Asterias will maintain access to the site’s manufacturing, laboratory and administrative space during this time, to advance its neurological development programmes.

The companies have also signed a $1m option license agreement for Asterias’ intellectual property (IP) relating to culturing pluripotent stem cells, such as hES cells, in suspension.

According to Asterias, the ‘Suspension Culture IP’ “maximises the production capacity inside a cell culture vessel, allowing for bulk proliferation of hES cells in a more efficient and cost-effective manner, which facilitates commercial production of important products for use in human therapies”.

The announcement marks Novo Nordisk’s most recent investment in stem cell technology, following a licensing deal signed between the Danish firm and the University of California San Francisco in May this year.

According to the agreement, Novo Nordisk will use the university’s technology to generate human embryonic stem cell lines for the development of regenerative therapies.

In addition, last month Novo Nordisk announced plans​ to restructure global operations, which includes increasing stem cell research in Copenhagen, Denmark.

Related news

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us


View more